大腸癌症診斷藥·治療藥的全球市場 - 成長·趨勢·預測
Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
|出版商||Mordor Intelligence LLP||商品編碼||353905|
|出版日期||內容資訊||英文 113 Pages
|大腸癌症診斷藥·治療藥的全球市場 - 成長·趨勢·預測 Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日期: 2019年04月01日||內容資訊: 英文 113 Pages||
面向本報告彙整全球大腸癌症診斷藥及治療藥的市場相關分析，彙整市場基本結構和最新形勢，主要的推動及阻礙市場要素，市場規模趨勢預測 (今後6年份)，模式 (各診斷/治療法) 及地區別詳細趨勢，市場競爭的動向 (各種資本交易等)，主要企業的簡介等資訊，為您概述為以下內容。
The colorectal cancer diagnostics and therapeutics market are expected to register a CAGR of nearly 4.6% during the forecast period, 2019-2024.
Colorectal cancer, also known as bowel cancer, colon cancer, or rectal cancer, and is any form of cancer that affects the colon and the rectum. The report tracks revenue generated by therapeutics used for the management of colorectal cancer, along with various screening tests, kits, and medical devices used for the diagnosis of colorectal cancer.
Immunotherapy Blockbusters to Remain a Significant Revenue Source For Leading Players Due to Label Expansions Despite Approaching Patent Expiry.
Bevacizumab (Avastin) is a monoclonal antibody that prevents tumors from growing in blood vessels, by antagonizing vascular endothelial growth factor (VEGF), which is a substance released by tumors to stimulate new blood vessel formation. The FDA approved a labeling extension for bevacizumab, administered in combination with intravenous 5-fluorouracil-based chemotherapy, for the second-line treatment of metastatic carcinoma of the colon or rectum. The approval of cyramza (ramucirumab) for second-line Avastin pre-treated metastatic setting, in 2016, is expected to propel the growth of the colorectal cancer drugs market, in the future.
The United States is Expected to Retain Largest Market Share During the Forecast Period
Geographically, the United States holds the largest market share with respect to demand and revenue. In 2017, 39,910 new rectal cancer cases and 95,520 new colon cancer cases were reported in the United States based on the estimates by the American Cancer Society. These estimates indicate that colorectal cancer is increasing its prevalence in the United States, which is in turn, leading to the growth of the market. The Asia-Pacific is also expected to witness a strong growth pattern in the coming years, with China and India showing rapid progress. In 2015, Roche signed an agreement with an insurance company in Shenzhen City. The Chinese people were among the first few to approve Avastin for reimbursement. This is expected to increase access to colorectal cancer therapeutics in China.
Several large drug and equipment manufacturers exist within the global colorectal cancer diagnostic and therapeutics market. Moreover, several new biotech firms are also active in the therapeutics segment. Key players in the market include Abbott Laboratories, Beckman Coulter, Clinical Genomics, Companion DX, EDP Biotech, Epigenomics AG, F. Hoffmann-La Roche AG, Novigenix, Quest Diagnostics, Siemens Healthineers, and VolitionRX, among others.